<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<META NAME="ROBOTS" CONTENT="NOINDEX, NOFOLLOW, NOARCHIVE" />
<meta name="dc.language" content="eng" />
<meta name="dc.title" content="Sollen v. Boehringer Ingelheim (Canada) Ltd. (November 28, 2008)" />	
<meta name="dc.date.created" content="2008-11-28" />
<meta name="dc.date.modified" content="2008-11-28" />
<title>Sollen v. Boehringer Ingelheim (Canada) Ltd. (November 28, 2008)</title>
<style>
<!--
h1
	{text-align:center;
	page-break-after:avoid;
	font-size:15.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h2
	{text-align:center;
	line-height:200%;
	page-break-after:avoid;
	font-size:15.0pt;
	font-family:"Times New Roman";}
h3
	{text-align:justify;
	font-size:13.0pt;
	font-family:"Times New Roman";}
h4
	{text-align:justify;
	line-height:200%;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{text-align:justify;
	tab-stops:center 3.0in right 6.0in;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{text-align:justify;
	tab-stops:center 3.0in right 6.0in;
	font-size:13.0pt;
	font-family:"Times New Roman";}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p.Doubleindent-quote, li.Doubleindent-quote, div.Doubleindent-quote
	{text-align:justify;
	tab-stops:1.5in;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.DOCKETINFOFIELD, li.DOCKETINFOFIELD, div.DOCKETINFOFIELD
	{text-align:right;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.Double-indent-subquote, li.Double-indent-subquote, div.Double-indent-subquote
	{text-align:justify;
	tab-stops:2.0in;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.headingNUMBER, li.headingNUMBER, div.headingNUMBER
	{text-align:justify;
	text-indent:0in;
	line-height:200%;
	tab-stops:.5in;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.COURTOFAPPEAL, li.COURTOFAPPEAL, div.COURTOFAPPEAL
	{text-align:center;
	font-size:15.0pt;
	font-family:"Times New Roman";}
p.StyleofCause, li.StyleofCause, div.StyleofCause
	{text-align:center;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.ParaNO, li.ParaNO, div.ParaNO
	{text-align:justify;
	line-height:200%;
	tab-stops:.5in;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.RespondentAppellant, li.RespondentAppellant, div.RespondentAppellant
	{text-align:right;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.Versus, li.Versus, div.Versus
	{text-align:center;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.Party, li.Party, div.Party
	{font-size:13.0pt;
	font-family:"Times New Roman";}
p.Panel, li.Panel, div.Panel
	{text-align:center;
	font-size:13.0pt;
	font-family:"Times New \(W1\)";}
p.HeadingNumber0, li.HeadingNumber0, div.HeadingNumber0
	{text-align:justify;
	
	line-height:200%;
	tab-stops:.5in;
	font-size:13.0pt;
	font-family:"Times New Roman";}
ol
	{ul
	{-->
</style>
</head>
<body bgcolor="#FFFFFF" vlink=purple lang=EN-CA>
<div class=Section1>
<table border=0 align="center" cellpadding=0 cellspacing=10>
    <tr>
      <td width=638 valign=top><p class=DOCKETINFOFIELD>CITATION:&nbsp;Sollen&nbsp;v.&nbsp;Boehringer
          Ingelheim (
          <st1:country-region w:st="on">
            <st1:place w:st="on">
            Canada</st1:country-region>
          ) Ltd.,&nbsp;2008 ONCA 803</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=DOCKETINFOFIELD>DATE: 20081128</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=DOCKETINFOFIELD>DOCKET: C48606</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=COURTOFAPPEAL>COURT OF APPEAL FOR ONTARIO</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Panel>Lang, Juriansz and Epstein JJ.A.</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p>BETWEEN</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=StyleofCause>Shirley Sollen, Lise Latulippe,
          Sandi Englund, Greg Williams, Murray Chuckrowski, Cheryl Shaw, Joyce
          Kamants, Pearl Bequette, May Viccars, Carol Walker, Darlene Kemp, Pfizer
          John Doe I, Pfizer John Doe II, Pfizer John Doe III, Pfizer John Doe
          IV, Pfizer John Doe V, Pfizer Jane Doe I, Pfizer Jane Doe II, Pfizer
          Jane Doe III, Pfizer Jane Doe IV, Pfizer Jane Doe V, Pfizer John Doe
          VI, Pfizer John Doe VII, Pfizer John Doe VIII, Pfizer John Doe IX,
          Pfizer John Doe X, Pfizer John Doe XI, Pfizer Jane Doe VI, Pfizer Jane
          Doe VIII, Pfizer Jane Doe IX, Pfizer Pharmacist John Doe I, Pfizer
          Dr. John Doe I, Pfizer Dr. Jane Doe I, Mobicox John Doe I, Mobicox
          John Doe II, Mobicox John Doe III, Mobicox John Doe IV, Mobicox John
          Doe V, Mobicox Jane Doe I, Mobicox Jane Doe II, Mobicox Jane Doe III,
          Mobicox Jane Doe IV, Mobicox Jane Doe V, Mobicox John Doe VI, Mobicox
          John Doe VII, Mobicox John Doe VIII, Mobicox John Doe IX, Mobicox John
          Doe X, Mobicox John Doe XI, Mobicox Jane Doe VI, Mobicox Jane Doe VII,
          Mobicox Jane Doe VIII, Mobicox Jane Doe IX, Mobicox Pharmacist John
          Doe I, Mobicox Dr. John Doe I, Mobicox Dr. Jane Doe I, and other John
          Does and Jane Does to be added</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=RespondentAppellant>Plaintiffs (Respondents)</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Versus>and</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=StyleofCause>Pfizer Canada Inc., Pfizer
          Inc., Pharmacia Canada Inc., Pharmacia Inc., <u>Boehringer Ingelheim
          (Canada) Ltd.</u>, Boehringer Ingelheim GMBH, Her Majesty the Queen,
          as represented by The Minister of Health Canada and the Attorney General
          of Canada</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=RespondentAppellant>Defendants (Appellant)</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Party>J. Scott Maidment and Lindsay Lorimer,
          for the appellant</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Party>John Legge and Casey R. Churko,
          for the respondent, Shirley Sollen</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Party>Emily Larose, for the respondent,
          Pfizer Canada Inc.</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Party>Heard and released
            orally: November 26, 2008</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p>On appeal from the order of Justice Maurice
          Cullity of the Superior Court of Justice dated February 21, 2008 and
          reported at 290 D.L.R. (4th) 603.</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Party align=center style='text-align:center'>ENDORSEMENT</p></td>
    </tr>
  </table>
  <p class=headingNUMBER style='line-height:normal'>[1]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The
    appellant appeals the decision of the motion judge that discontinued the
    respondents’ national class action and dismissed the appellant’s claim for
    an anti-suit injunction.  </p>
  <p class=headingNUMBER style='line-height:normal'><span>[2]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>The
    appellant concedes that if he loses the appeal from the discontinuance decision,
    then his appeal of the non-suit decision cannot succeed.  We will begin with
    the appeal of the discontinuance decision.  </p>
  <p class=headingNUMBER style='line-height:normal'><span>[3]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>The
    motion judge approved the discontinuance under s. 29 of the <i>Class Proceedings
    Act</i>, S.O. 1992, c. 6, s. 29.  The requirement for approval is intended
    for the protection of the interests of the absent class members.  The motion
    judge determined that those interests would not be prejudiced by the discontinuance.  We
    are not persuaded of any error in the motion judge’s reasons for the approval
    of the discontinuance.  </p>
  <p class=headingNUMBER style='line-height:normal'><span>[4]<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span>This
    disposes of the motion for the anti-suit injunction, which presumed the continuance
    of the action in
    <st1:place w:st="on">
    <st1:State
 w:st="on">
    Ontario. </p>
  <p class=headingNUMBER style='line-height:normal'>[5]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>While
    we recognize that there are important issues surrounding national class proceedings
    commenced in multiple jurisdictions, the facts of this case do not provide
    the appropriate foundation for a consideration of those issues.  </p>
  <p class=headingNUMBER style='line-height:normal'>[6]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Costs
    are awarded to the respondents in the agreed-upon amount of $5,000, inclusive
    of disbursements and Goods and Services tax.  </p>
  <p>                                                                                                                        “S.E.
    Lang J.A.”</p>
  <p>                                                                                                                        “R.G.
    Juriansz J.A.”</p>
  <p>                                                                                                                        “G.
    Epstein J.A.”</p>
</div>
</body>
</html>
